Share-Based Compensation (Tables)

6 Months Ended

Jun. 29, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Compensation Expense and Related Income Tax benefit

The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):

	Three Months Ended				Six Months Ended
Compensation costs and related income tax benefit	June 29, 2024		July 1, 2023		June 29, 2024		July 1, 2023
Cost of sales	$	2	$	2	$	4	$	3
Selling and marketing	8		1		13		7
Research and development	12		6		18		13
General and administration	15		(6)		23		3
Total compensation expense	$	37	$	3	$	58	$	26
Income tax benefit	$	6	$	3	$	10	$	7

Schedule of Restricted and Performance Stock-settled Awards

A summary of the Company’s restricted and performance stock-settled awards for the six months ended June 29, 2024 is as follows:

	RSUs			PSUs			RSAs
	Units	Weighted-Average Grant Date Fair Value		Units	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of period	437,379	$	299.19	195,932	$	334.59	433	$	477.74
Granted	271,704	308.89		88,029	309.05		6,264	319.95
Released	(176,502)	323.37		(35,597)	482.42		(6,697)	330.15
Forfeited	(7,971)	296.31		(1,428)	296.59		—	—
Outstanding at end of period	524,610	$	296.14	246,936	$	304.49	—	$	—

Schedule of SARs Activity

	SARs	Weighted-Average Exercise Price
Outstanding at beginning of period	398,838	$	124.96
Exercised	(126,582)	100.02
Expired	(2)	86.80
Outstanding at end of period	272,254	$	136.48
Exercisable at end of period	270,999	$	135.42

Schedule of SARs Outstanding

The following table summarizes information about SARs outstanding as of June 29, 2024:

	Outstanding		Exercisable
Aggregate intrinsic value (in millions)	$	47	$	47
Weighted-average remaining contractual life (in years)	1.7		1.7